Shukla Sanjay 4
4 · aTYR PHARMA INC · Filed Feb 6, 2024
Insider Transaction Report
Form 4
aTYR PHARMA INCLIFE
Shukla Sanjay
DirectorPresident and CEO
Transactions
- Exercise/Conversion
Restricted Stock Unit
2024-02-05−10,375→ 20,750 total→ Common Stock (10,375 underlying) - Exercise/Conversion
Common stock
2024-02-05+10,375→ 116,548 total
Footnotes (3)
- [F1]Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on February 3, 2022.
- [F2]Restricted stock units convert into common stock on a one-for-one basis.
- [F3]The RSUs vest in four equal annual installments beginning on February 3, 2023, such that the RSUs will fully vest on February 3, 2026. The RSUs are subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.